What is the role of erdafitinib in the treatment of metastatic bladder cancer?

Updated: Feb 23, 2021
  • Author: Kara N Babaian, MD, FACS; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
  • Print

Erdafitinib inhibits fibroblast growth factor receptor (FGFR) phosphorylation and signaling, and thereby decreases cell viability in cell lines expressing FGFR genetic alterations, including point mutations, amplifications, and fusions. FGFRs regulate important biological processes including cell proliferation and differentiation, which are part of a complex signaling pathway in tumorigenesis. 

The FDA granted erdafitinib accelerated approval in April 2019 for locally advanced or metastatic urothelial carcinoma that has FGFR2 or FGFR3 genetic alterations and progressed during or following at least 1 line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Approval was based on a multicenter, open-label, single-arm study (n=87) of patients in which the overall response rate was 32.2%, with 2.3% of patients having a complete response and almost 30% having a partial response. [141]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!